Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | BACE1 | P56817 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | METAP1 | P53582 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22495425 | 0.85 | KMT2A (0.74) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL22495266 | 0.85 | MAPT (0.51) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL22495439 | 0.85 | MAPT (0.51) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL6427075 | 0.85 | GAA (0.65) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL28462375 | 0.85 | MAPT (0.51) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL28457074 | 0.85 | MAPT (0.51) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL7954746 | 0.82 | MAPT (0.68) | KMT2AMAPTGAAKDM4EPOLB | |
| SCHEMBL11508407 | 0.82 | KDM4E (0.70) | KMT2AMEN1MAPTGAAKDM4E | |
| SCHEMBL22495524 | 0.82 | MAPT (0.63) | KMT2AMEN1ATMMAPTGAA | |
| SCHEMBL22495265 | 0.81 | KMT2A (0.57) | KMT2AMEN1ATMMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | Sanford Burnham Prebys Medical Discovery Institute | 2022-03-03 | — | — | US | disclosed |
| EP-3833352-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | University of Central Florida Research Foundation, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-4788196-A | Phenyl piperazine anti-arrhythmia agents | PFIZER INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0244115-A2 | Phenyl-piperazine anti-arrhythmia agents | Pfizer Limited (GB) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | KMT2A 2545/4885MEN1 4703/4885ATM 2864/4885 |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | ANXA6, ANXA1, ANTXR2 | KMT2A 307/4885MEN1 1353/4885ATM 1720/4885 |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | ENY2, ANTXR2, ALAD | KMT2A 3645/4885MEN1 359/4885ATM 575/4885 |
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | KMT2A 4463/4885MEN1 311/4885ATM 3155/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | KMT2A 573/4885MEN1 616/4885ATM 3430/4885 |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | SLC19A1, PNMT, SRM | KMT2A 573/4885MEN1 616/4885ATM 3430/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | KMT2A 308/4885MEN1 1999/4885ATM 526/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | KMT2A 4496/4885MEN1 326/4885ATM 3273/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | KMT2A 2476/4885MEN1 4749/4885ATM 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.